<DOC>
	<DOCNO>NCT00002025</DOCNO>
	<brief_summary>To make intravenous ( IV ) ganciclovir available immunocompromised patient life-threatening sight-threatening Cytomegalovirus ( CMV ) infection , symptom disease severe allow admission control clinical study ganciclovir therapy . To determine safety tolerance 2 - 3 week induction course ganciclovir IV follow maintenance course ganciclovir IV indefinite duration . To tabulate patient 's clinical response .</brief_summary>
	<brief_title>Open Label Ganciclovir Therapy Sight- Life-Threatening Cytomegalovirus Disease Immunocompromised Patient</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients follow exclude : Cytomegalovirus ( CMV ) disease meet criterion treatment IND protocol , clinical study , include control clinical study anticytomegalovirus therapy peripheral CMV retinitis patient AIDS . Mild moderate CMV infection fail meet severity criterion . CMV syndrome ( i.e. , cytopenia , increase liver enzymes , fever , viremia , viruria ) consider immediately lifethreatening . Transplant patient trial reduction immunosuppressive drug treatment feasible . Children congenital neonatal CMV document primary acquire immunodeficiency . Hypersensitivity acyclovir ganciclovir . Receiving antimetabolite treatment discontinue . Concurrent Medication : Excluded : Antimetabolites . Alkylating agent . Nucleoside analog ( topical ophthalmics permit ) . Interferon . Foscarnet . Cytokines . Patients follow exclude : Cytomegalovirus ( CMV ) infection meet criterion treatment IND protocol , clinical study , include control clinical study anticytomegalovirus therapy peripheral CMV retinitis patient AIDS . Mild moderate CMV infection fail meet severity criterion . CMV syndrome ( i.e. , cytopenia , increase liver enzymes , fever , viremia , viruria ) consider immediately lifethreatening . Transplant patient trial reduction immunosuppressive drug treatment feasible . Children congenital neonatal CMV document primary acquire immunodeficiency . Hypersensitivity acyclovir ganciclovir . Receiving antimetabolite treatment discontinue . Patients must qualify follow : Previously enrol compassionate use study ( ICM 1257/1257A ) terminate another Syntex ganciclovir study . Diagnosis AIDS lifethreatening Cytomegalovirus ( CMV ) infection . Diagnosis immunodeficiency AIDS , lifethreatening sightthreatening CMV disease .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1989</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Immune Tolerance</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>